Research Finds Connected Pens Significantly Reduce Missed Doses and Improves Time in Recommended Glucose Range
Gothenburg, Sweden (PR NEWSWIRE) — November 9, 2021 – Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, announced a strategic collaboration with Novo Nordisk that will benefit people with diabetes in Germany, and other European markets, through the development of connected insulin pen solutions. Through this collaboration, the companies are integrating two new connected or “smart” insulin pens, NovoPen® 6 and NovoPen Echo® Plus, with Glooko’s mobile apps and cloud-based platforms.
Glooko’s platforms are compatible with more than 95 percent of diabetes devices globally. This collaboration with Novo Nordisk now expands upon the company’s device-agnostic model for remote patient monitoring and data management, expanding and customizing care management options for people with diabetes and their healthcare providers.
The new smart pens automatically record dosage times and amounts, storing up to three months of such data and enabling them to be transferred into the Glooko platform. Different from conventional insulin pens, which require the user to manually record all the data involved with each insulin dose, the new smart pens not only facilitate the uninterrupted digital recording of insulin dosing data, but also provide the possibility to transfer the recorded data via near-field communication NFC.
With the integration of the reporting and analytics functions of the Glooko® platform, the new smart pens enable patients to capture all their dosing data and help them and their providers quickly recognize data about missed insulin doses. The Glooko integration also makes it possible for patients to view data via graphically-oriented reports that can help them recognize trends so they can take action to improve their treatment plan.
“Glooko is very pleased to partner with Novo Nordisk on this integration of our products,” said Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes. We are excited about the continued expansion of our working relationship with Novo Nordisk and look forward to providing more innovative products in the very near future for people in Germany looking to improve their health care regimens.”
NovoPen 6, in fact, was used by patients in the first real-world outcomes study using smart pens in clinical practice, which was conducted recently at 12 diabetes clinics across Sweden. The study showed that patients reduced the number of missed insulin bolus doses at mealtime by 43 percent (P=0.002). They also significantly increased the proportion of time their glucose levels stayed in the recommended range from 41.4 to 49.9 percent of the time (P<0.001).
Glooko is the global leader in diabetes patient data with over 32 billion data points. Adding Novo Nordisk’s connected insulin pens in additional global markets will increase this data at Glooko, and benefit healthcare providers and clinical researchers around the world, via access to real world data and applying it to studies for improved therapeutics for patients with chronic conditions.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms, Glooko® and diasend®, empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 29 countries across 22 languages. Learn more at glooko.com.
# # #
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media, Europe
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888
Prakash Menon brings extensive AI and enterprise software expertise to the global leader in connected chronic care management
Palo Alto, CA, August 9, 2021 /PR NEWSWIRE/ — Glooko Inc., the leading provider of remote patient monitoring and data management platforms in diabetes and related chronic conditions, today announced the appointment of Prakash Menon as the Company’s Chief Technology Officer.
As a proven technology executive with more than 30 years of experience in enterprise software development, Menon will bring deep enterprise software expertise to Glooko’s goal of building the most innovative digital platforms that connect people with chronic conditions and their care providers, for better health outcomes.
Menon has an extensive track record in SaaS, enterprise software development, AI, technical leadership, and entrepreneurial experience. In addition to enterprise application development, his areas of expertise include distributed systems integration, database (SQL and NoSql) in and out of the cloud and building and deploying machine learning (ML) models to production scale. He has built and led teams that deliver solutions that require ML, business analytics, application development, mobile development and open API development.
Most recently he served as Chief Technology Officer of Genalyte and delivered a multi-antigen analysis algorithm for a COVID-19 antibody test using ML in three weeks, leading to an investment by Verily (Google Health).
Prior to this, Menon spent 7 years in the roles of CTO, Interim CEO and Board Member at BaseHealth. During his time at BaseHealth his team built and delivered five novel AI products that use ML and deep learning to accurately predict the onset of the world’s most devastating diseases. His team architected an ML platform that processed 350 million data points over 263,000 lives across hybrid cloud technologies.
Menon’s unique software perspective and his extensive background in creating and scaling large-scale cloud software systems will serve Glooko’s global patient base, healthcare providers and technology partners, at a time when the industry is tackling the challenges of standardization and scale within digital healthcare. Glooko currently provides remote patient management and connected care platforms in diabetes and related chronic conditions such as obesity and hypertension. With recent funding, the Company is expanding into additional indications and global markets.
“I’m excited to join Glooko and help the team scale to deliver superior platforms for connecting patients with their healthcare providers for better care,” Menon said. “I’m impressed with Glooko’s proven technology that has shown to improve outcomes for people with chronic diseases, and I’m ready to help make that happen at a whole new level.”
Russ Johannesson, Chief Executive Officer at Glooko stated, “We are so pleased to welcome Prakash to our Executive Leadership Team. He brings an impressive track record of leading successful teams in building healthcare enterprise systems and scaling those systems for rapid growth. Even in a place such as Silicon Valley, his credentials stand out. We are excited to see him take Glooko’s products to next-level.”
Johannesson continued, “Additionally, we are very proud of the contributions that Kyle Brown, our outgoing CTO has made at Glooko. His impact in his time here has been very positive to building Glooko’s platforms to where they are today for our worldwide patients and healthcare providers. We wish him all the best and a very happy retirement.”
About Glooko
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected weight scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 28 countries across 21 languages. Learn more at glooko.com.
Media Contacts:
Tanya Rodante
Director of Global Communication, Glooko
[email protected]
Presented at 2021 Annual Meeting of the American Diabetes Association
WASHINGTON, June 25, 2021 /PRNewswire/ — A study of the use of remote patient monitoring (RPM) with diabetes patients demonstrated improved and sustained glycemic control at 3-, 6- and 12-month intervals among people with type 2 diabetes (PWT2D). Participants remotely shared their glucose data with care teams and received remote-based coaching interventions. The data will be presented during a poster session beginning today at the 81st Scientific Sessions (virtual) of the American Diabetes Association and are sponsored by Glooko, Inc.
The study investigated whether PWT2D demonstrated improved glycemia after participating in RPM programs of varied scope and duration at 11 different healthcare systems across the United States. Program participants were instructed to regularly sync their blood glucose meters with either a mobile app or a computer-based software during the program. Synced glucose data were made available to the RPM care teams via a web-based dashboard, and remote coaching was administered either regularly and/or as needed. The study’s analyses evaluated glycemic outcomes derived from self-monitoring of blood glucose (SMBG) data recorded from RPM program participants at various intervals throughout the RPM program (up to 12 months).
The results show immediate (3 months) and sustained (6 and 12 months) glycemic improvement compared to baseline (all Ps < .05), including:
1. Decrease in average glucose by ~12% (~20 mg/dL)
2. Increase in the average proportion of in-range (70-180 mg/dL) glucose readings by ~22% (~13 percentage points)
3. Decrease by ~42% (~6 percentage points) in the average proportion of high glucose readings (>250 mg/dL)
The analysis included 424 PWT2D among whom 46% were females and the median age [IQR] was 50 [42-59] years. Cross-sectional comparisons were made at the start of the program and at 3 (N3 = 331), 6 (N6 = 228), and 12 months (N12 = 129) of RPM program participation.
“The emergence of digital health tools like connected devices and mobile apps for self-management has not only helped people with type 2 diabetes in the daily management of their disease but also facilitated the sharing of their data with their care teams,” said Mark Clements, MD, PhD, Chief Medical Officer of Glooko and practicing endocrinologist. “These results demonstrate that, with access to patient data, care teams can identify patients with sub-optimal glycemic control and provide them with timely, remote-based interventions outside of routine clinic visits that lead to significant glycemic improvements in the near term as well as on a sustainable basis.”
The analysis also found that the average proportion of hypoglycemic readings (<70 mg/dL) did not change.
The poster at the virtual ADA meeting is # 467-P, “Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes,” by Tong Sheng, PhD, Sarine Babikian, PhD, Vikram Singh, M Eng, and Mark A. Clements, MD, PhD.
Additionally at ADA, the Company will present the following on-demand panel:
Registered attendees of the 81st Scientific Sessions of the American Diabetes Association will have on-demand access online to “Between Two Appointments: How to Leverage Daily Diabetes Data (In-clinic & Remote) to Improve Patient Outcomes,” an expert-led ADA Diabetes Learning Byte panel. This 20-minute discussion will be with endocrinologist Mark Clements, MD, PhD, Chief Medical Officer, Glooko and Zach Henderson, Chief Commercial Officer, Glooko, both industry veterans with extensive background in healthcare data and analytics. They will explore how to leverage patient diabetes data captured by glucose meters, pumps, smart pens, fitness and health apps, and other wearables and use it in ways that lead to healthy patient outcomes. They will also discuss available solutions for remotely using patient-collected data between appointments to better inform care plans and address emerging risks. The on-demand presentation will be available June 25 through September 29 via the registration of ADA attendees at https://professional.diabetes.org/meetings/81st-registration-information.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. The platforms are compatible with over 95% of global diabetes devices along with biometric devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefitted from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 28 countries across 21 languages. Learn more at glooko.com.
Media Contact:
Tanya Rodante
Director of Global Communication, Glooko
[email protected]
Gothenburg, Sweden (PR NEWSWIRE) May 6, 2021 Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, today announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions. The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen™ and Tempo Smart Button™ (currently in late-stage development) with Glooko’s platform.
Glooko’s platforms are compatible with over 95 percent of diabetes devices globally, and the Lilly collaboration expands upon the Company’s device-agnostic model for remote patient monitoring and patient data management. This gives patients and their healthcare providers more freedom of choice for managing their care.
The Tempo Pen is an enhanced version of Lilly’s current prefilled, disposable insulin pen to which the Tempo Smart Button (pending CE mark) attaches. Through this new agreement, the Tempo Smart Button will pair with Glooko’s software to facilitate the integration of personalized healthcare data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs. The integrated and actionable insights available in Glooko will improve the standard of diabetes care.
“Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch,” said Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes. We are excited about continuing to expand the availability of our solution and look forward to helping more people manage their diabetes through our innovative products.”
Lilly aims to receive CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button with Glooko’s platform following this certification.
“We’re pleased to work alongside Glooko on our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community,” said Marie Schiller, Vice President of Product Development for Connected Care and Insulins at Lilly. “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses. By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.”
Glooko is the global leader in diabetes patient data with over 32 billion data points. Adding Lilly’s connected insulin pens in additional global markets will increase this data at Glooko, and benefit healthcare providers and clinical researchers around the world, via access to real world data and applying it to studies for improved therapeutics for patients with chronic conditions.
About Diabetes
An estimated 463 million adults worldwide(1) have diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.(2)
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.
About Glooko
glooko.com.
Contacts:
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media Europe
Anders Sonesson
General manager EMEA/APAC, Glooko
[email protected]
+46735458888
_________
(1) International Diabetes Federation. IDF Diabetes Atlas, 9thedn. Brussels, Belgium: International Diabetes Federation, 2019. Available at:http://diabetesatlas.org.
(2) Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services; 2020.
New Capital Reflects the Company’s Increasing Trajectory and Market Growth
PALO ALTO, CA, March 16, 2021 /PRNewswire/- Glooko Inc., a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity has raised a $30 million Series D round of funding. The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic. Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s broad and growing product line of advanced digital health solutions.
“Glooko has done a remarkable job of bringing to market cutting edge digital healthcare platforms, which empower people with diabetes to better manage their disease and improve their lives. This technology enables physicians to take better care of patients with diabetes by strengthening the engagement between people with diabetes and their healthcare providers,” said Charles Boorady, Founder & Managing Partner of Health Catalyst Capital. “As a result of Glooko’s innovations, the company has experienced rapid market adoption growing its global ecosystem to more than 7,500 clinics and has entered into partnerships with many of the world’s largest diabetes medical device companies and pharmaceutical companies as well as top healthcare systems. We look forward to supporting the company in its next phase of growth as it invests in new capabilities supporting the management of chronic care and serving even more stakeholders.”
This round of financing follows a successful 2020 for Glooko, the most successful in its history despite the global pandemic. Last year, the Company’s growth included key partnerships with major healthcare systems and extended long-term existing partnerships with several global diabetes industry leading companies such as Insulet and Novo Nordisk.
The new proceeds will accelerate execution of Glooko’s commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas.
This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for,” said Russ Johannesson, CEO of Glooko. “Now more than ever, the healthcare industry is seeking new and smarter technologies, whether it’s for patient care or researching new therapies. I am excited to lead the team at Glooko in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions with their healthcare professionals.”
About Glooko
Glooko is transforming digital health by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. Over 3 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 27 countries across 20 languages. Their US headquarters are located in Palo Alto, CA with European headquarters in Gothenburg, Sweden. Learn more at glooko.com
About Health Catalyst Capital
Health Catalyst Capital Management is an independent fund manager investing in private, growth-stage healthcare information technology and technology-enabled services businesses that seek to improve the human condition and promote value-based care.
HCC was formed by a team of experienced healthcare investors and operators seeking profitable investment opportunities, while at the same time seeking to improve the human condition and promote value-based care.Learn more at healthcatalystcapital.com
Investors
Steve Lien
Chief Financial Officer, Glooko
+1650-720-5310
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]
Media, Europe
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888
New education platform focuses on diabetes technology training, data management and remote patient monitoring (RPM)
Gothenburg, Sweden (PR NEWSWIRE) — October 28, 2020 — Glooko AB (“Glooko” or “The Company”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), a new online medical education programme for clinicians who treat people with diabetes in the UK. The programme will help clinicians keep their knowledge base current on the ever-growing assortment of new diabetes technologies that manufacturers make available to people with diabetes. It was inspired after discussions with the National Health Service England (NHSE), as part of its effort to ensure that all healthcare professionals learn uniformly about technology.
Currently, the number of people diagnosed with diabetes in the UK is estimated to be 3.5 million and expected to rise to 5 million by 2025.1
For people with diabetes and their healthcare providers, managing the myriad technologies like glucose monitors and insulin pumps, and the data volume that accompany these technologies, is a well-established challenge. And while tech-based services like web-based programs, telehealth, mobile apps and remote monitoring are improving users’ accessibility and connectivity, the adoption of these innovations has been slow.2
The Academy™ education programme focuses exclusively on diabetes health tech, and includes an extensive range of online courses for healthcare professionals (HCPs), with the intent to increase knowledge, training and usage of these devices – ultimately improving outcomes. All courses are accessed as video modules through the diasend® diabetes data management app and portal, via the DigiBete Global platform.
The programme is available to all diabetes healthcare professionals in the UK at no cost, and is funded in part via sponsorships from global industry partners like Abbott, AgaMatrix, Dexcom, Insulet, Medtronic and Roche Diabetes Care.
Another goal of the educational platform is to reduce barriers to the adoption of diabetes digital tools. DTN UK/ABCD provides guidance on educational content and ensures that the programme aligns with current and future National Health Service England (NHSE) policy/pathways. Healthcare professionals earn CPD accreditation for completing the programme.
“Academy™ is an important investment that sets a new standard for professional development in the diabetes medical technology industry,” said Russ Johannesson, Chief Executive Officer of Glooko. “In collaboration with the NHSE and DTN UK/ABCD, we’ve developed a new, extensive curriculum that will not only equip HCPs to access training that is relevant to their technology skills development, but it will also build a wider range of their capabilities as we move increasingly towards a remote patient monitoring (RPM) environment.”
The curriculum covers over 95% of the diabetes device manufacturers and their technologies, and HCPs that complete the programme will receive Continuing Professional Development accreditation as well as DTN UK/ABCD certification.
“As diabetes technology becomes increasingly widespread in routine clinical practice, we need to train all levels of our diabetes and wider health workforce in what these technologies are and how to use the large amounts of data they generate,” Professor Pratik Choudhary, Professor / Honorary Consultant in Diabetes and Chair of DTN UK, said. “Use of these technologies has transformed how we deliver care, especially during these challenging times. We firmly believe that the collective efforts that we’re cultivating with world-class digital health companies like Glooko will create more value and positively impact outcomes that matter to people with diabetes.”
Prof. Partha Kar, National Specialty Advisor of Diabetes at NHS England, stated “As Nick Fury once said in The Avengers ‘There was an idea’. It’s been a pleasure to bring together multiple partners across industry, specialists in diabetes care – facilitated by Glooko for this project. As diabetes technologies continually advance and improve, it’s critical that healthcare providers have access to the most exceptional training on the plethora of devices that people with diabetes use on a daily basis. This platform will hopefully go a long way in ensuring education is available uniformly across the NHS – and thereby improving access and outcomes for those living with diabetes.”
Glooko is committed to incorporating newly-developed, online immersive education experiences that complement Glooko’s portfolio of industry-leading diabetes digital health solutions.
The Academy™ programme is part of Glooko’s global mission to improve health outcomes by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research and improved collaboration.
Rollout of the programme will begin in November 2020 to coincide with World Diabetes Day.
For more information about Academy™: get.glooko.com/academy.
ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. 2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.
Sources:
1. Diabetes Facts and Stats: 2015 – Diabetes UK, 2015
2. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association Diabetes Care / American Diabetes Association (ADA) – June 8, 2020
Media Contacts:
Glooko Inc: [email protected]
MOUNTAIN VIEW, Calif, Aug 12, 2020 – As Glooko continues its journey to transform digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration, today they announced the addition of Tracy Bahl and Mike Doherty as independent members of the Board of Directors to provide guidance and support to the continued growth of the business.
“We are very excited to welcome Mike and Tracy to Glooko,” says Russ Johannesson, CEO at Glooko. “We are proud of our distinguished and active board of directors and Tracy and Mike will complement them with their extensive experience. From the start, Glooko has been dedicated to making the lives of people with diabetes easier, and I am convinced that the addition of our new members will add tremendous value supporting our rapid growth in telehealth and clinical research, in both existing and new geographies.”
Bahl, with an extensive background in senior leadership roles at healthcare companies such as CVS Health and UnitedHealth Group, brings expertise in health plan growth and operations, revenue cycle management and healthcare services. As Glooko expands its global provider footprint and partners with payers and employers, Bahl will be tapped for his expertise and guidance.
“I’m thrilled about the opportunity to join Glooko as a board member and be part of this exciting journey”, Bahl said. “This company provides a unique value proposition for patients, providers and payers, and I see a huge potential for Glooko’s services in support of remote care and remote patient monitoring. With the COVID-19 pandemic, which has affected us all, we’ve seen the need and value of telehealth has grown immensely. As we head into the new normal, Glooko can really make a difference by enabling collaboration and remote care in healthcare.”
Doherty joins Glooko’s board with an in-depth knowledge and experience in regulatory affairs, pharmaceutical development, data strategy and clinical research, from a distinguished career in global companies such as AstraZeneca, Roche and Foundation Medicine where he held a variety of senior leadership roles. With Glooko’s focus on enabling virtual clinical studies and global expansion into new markets, Doherty’s experience is particularly valuable.
“I am excited to be part of Glooko’s board of directors”, Doherty said. “I see a great potential for Glooko to add value in the field of clinical research and real world data by enabling clinical trials globally. I look forward to contributing to the global expansion of this exciting company as it transitions into its next phase of growth.”
ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.
Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.
2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.
MOUNTAIN VIEW, Calif, July 9, 2020 – Together, with Sanofi’s nearly 100-year heritage in diabetes and Glooko’s leadership in remotely connecting people living with diabetes and health care professionals, the companies will collaborate to provide people with diabetes with a digital health solution* to help manage their disease under the virtual guidance of their care teams.
The Glooko Remote Care Solution enables people with diabetes to upload and share data from their diabetes devices with their care providers, who can remotely review diabetes data on the Glooko software platform. Healthcare providers can then provide medical guidance to the person with diabetes via phone, text, or email, bypassing the need for a clinic visit. It is currently being provided free of charge, as a public service to broaden access to telehealth and remote diabetes care during the COVID-19 pandemic.
“At the onset of the pandemic, we quickly realized that we were in a unique position to make a significant contribution towards keeping the diabetes community safe by enabling telehealth and free remote care,” says Russ Johannesson, CEO at Glooko. “We are thrilled to join forces with Sanofi, who share our focus on improving the lives of people with diabetes. Their extensive experience and broad network will support making remote care accessible for even more clinics and people with diabetes.”
“While the world continues to face many challenges as a result of the pandemic, Sanofi is excited to share the Glooko Remote Care Solution with healthcare providers focused on managing diabetes and their patients,” says Chris Boulton, Head of US Diabetes Marketing at Sanofi. “This collaboration puts patient care at the forefront, especially during this stressful time where there is a need for more seamless virtual care.”
To learn more and sign up for Glooko Free Remote Care, visit glooko.com
*Sanofi is not contributing to nor subsidizing the free offer.
ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.
Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.
2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.
Transformative Healthcare Technology Entrepreneur joins leader in diabetes data management
MOUNTAIN VIEW, Calif., April 9, 2020 — As part of its continued focus on delivering data enabled solutions to improve the lives of people with diabetes, Glooko, the leader in diabetes digital health, data management solutions and remote monitoring solutions, today announced the appointment of Kyle Brown as Chief Technology Officer.
Brown joins Glooko with an extensive executive background in digital health, where he has successfully built several technology companies focused on the shift from clinician-entered proprietary registries to open and inclusive Patient Insight Networks.
“We’re very excited to have Kyle joining our company at this important time in our development. His extensive experience building data-driven healthcare technology businesses, together with his unique background in software development, patient advocacy, and support of clinical research, will be incredibly valuable for Glooko as we continue to grow” said Russ Johannesson, CEO of Glooko.
In his new role with Glooko, Brown will have global responsibility for all technology and engineering efforts
“Glooko’s work enhancing the patient-clinician relationship, especially in these times of accelerating adoption of remote care and telemedicine technologies, is a perfect match with my passion for leveraging the digital content to improve patient care,” Brown said. “I am very excited to be a part of the company’s global expansion to create new ways to better engage people with diabetes”.
Brown comes to Glooko from PatientCrossroads/AltaVoice, which he founded and led for over a decade. The company’s mission was to harness the collective knowledge of patient communities to drive faster treatments while creating a market for patient provided data. As CEO, Brown led the implementation of over 125 patient registry programs collecting data on more than 400 diseases in collaboration with advocacy, academia, government and pharmaceutical companies.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts
For inquiries, please email [email protected].
STATEMENT FROM GLOOKO RE: COVID-19 SERVICE
MOUNTAIN VIEW, Calif., March 19, 2020 — Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed to helping ensure the health and well-being of people with diabetes, their caregivers, and their healthcare professionals. Glooko is therefore taking action to serve the global diabetes community by providing a no-charge remote-care solution that provides live patient-to-clinician connectivity.
As many efforts undertaken in our communities are aimed at reducing the chances of being exposed to and spreading COVID-19, that individuals who have chronic conditions like diabetes and contract the virus appear to be at a higher risk for developing complications; as such limiting exposure is critical. For certain appointments, healthcare professionals may determine that the patient and their care team would be best served by a remote review of the patient’s personal diabetes data and a corresponding telehealth consult, reserving in-office visits only for those appointments where a patient’s medical status truly requires in-person treatment.
To minimize the risk to people with diabetes during this time by broadening access to remote medical appointments with healthcare providers, Glooko is offering its secure, privacy-protected remote-care solution at no charge to medical clinics and people with diabetes as a public service until the greatest threat of the pandemic has subsided.
This public service is being made available to medical clinics and people with diabetes in countries where Glooko technology is already provided. Interested medical clinics and people with diabetes can learn more about how to access the Glooko remote-care solution at www.glooko.com.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® by Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts
For inquiries, please email [email protected].